Dietary and genetic disruption of hepatic methionine metabolism induce acid sphingomyelinase to promote steatohepatitis

Alarcón‐Vila, Cristina; Insausti-Urkia, Naroa; Torres, Sandra; Segalés-Rovira, Paula; Rosa, Laura Conde de la; Núñez, Susana; Fucho, Raquel; Fernández-Checa, José C.; Garcı́a-Ruiz, Carmen

doi:10.1016/j.redox.2022.102596

Cited by 6 publications

(2 citation statements)

References 54 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SAM and SAH levels were determined from deproteinized extracts (w/v 1:1 with perchloric acid 0.5 M) by HPLC, using a 5-μm Hypersil C-18 column (250 × 4.6 mm) as described [ 48 ]. The isocratic elution was carried out with 40 mM ammonium phosphate, 8 mM heptane sulfonic acid, and 6% acetonitrile, pH 5.0 adjusted with 70% perchloric acid at a flow rate of 1.0 ml/min.…”

Section: Methodsmentioning

confidence: 99%

S-Adenosyl-l-methionine restores brain mitochondrial membrane fluidity and GSH content improving Niemann-Pick type C disease

Goicoechea,

Torres,

Fàbrega

et al. 2024

Redox Biology

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

S-Adenosyl-l-methionine restores brain mitochondrial membrane fluidity and GSH content improving Niemann-Pick type C disease

Goicoechea,

Torres,

Fàbrega

et al. 2024

Redox Biology

Self Cite

View full text Add to dashboard Cite

“…Additionally, recent findings link ASMase activity to alterations in S -adenosyl- l -methionine (SAM) and phosphatidylcholine (PC) balance, indicating that inhibiting ASMase and improving PC and methionine metabolism may be an effective way to treat ASH/NASH (Alarcón-Vila et al 2023 ).…”

Section: Potential Functions Of Asmase In Liver Anomaliesmentioning

confidence: 99%

The relevance of acid sphingomyelinase as a potential target for therapeutic intervention in hepatic disorders: current scenario and anticipated trends

Mir

Thirunavukkarasu

2023

Arch Toxicol

View full text Add to dashboard Cite

Acid sphingomyelinase (ASMase) serves as one of the most remarkable enzymes in sphingolipid biology. ASMase facilitates the hydrolysis of sphingomyelin, yielding ceramide and phosphorylcholine via the phospholipase C signal transduction pathway. Owing to its prominent intervention in apoptosis, ASMase, and its product ceramide is now at the bleeding edge of lipid research due to the coalesced efforts of several research institutions over the past 40 years. ASMase-catalyzed ceramide synthesis profoundly alters the physiological properties of membrane structure in response to a broad range of stimulations, orchestrating signaling cascades for endoplasmic reticulum stress, autophagy, and lysosomal membrane permeabilization, which influences the development of hepatic disorders, such as steatohepatitis, hepatic fibrosis, drug-induced liver injury, and hepatocellular carcinoma. As a result, the potential to modulate the ASMase action with appropriate pharmaceutical antagonists has sparked a lot of curiosity. This article emphasizes the fundamental mechanisms of the systems that govern ASMase aberrations in various hepatic pathologies. Furthermore, we present an insight into the potential therapeutic agents used to mitigate ASMase irregularities and the paramountcy of such inhibitors in drug repurposing.

show abstract

Reply to: “Hyperhomocysteinemia predicts liver-related clinical outcomes in the general population”

Tripathi¹,

Singh²,

Yen³

2023

Journal of Hepatology

View full text Add to dashboard Cite

Dietary and genetic disruption of hepatic methionine metabolism induce acid sphingomyelinase to promote steatohepatitis

Cited by 6 publications

References 54 publications

S-Adenosyl-l-methionine restores brain mitochondrial membrane fluidity and GSH content improving Niemann-Pick type C disease

S-Adenosyl-l-methionine restores brain mitochondrial membrane fluidity and GSH content improving Niemann-Pick type C disease

The relevance of acid sphingomyelinase as a potential target for therapeutic intervention in hepatic disorders: current scenario and anticipated trends

Reply to: “Hyperhomocysteinemia predicts liver-related clinical outcomes in the general population”

Contact Info

Product

Resources

About